In an era of drug development in which everyone seems to be raising money for an immuno-oncology start-up, it's remarkable that the biggest initial public offering in the US by a biopharmaceutical company in 2017 was done by Denali Therapeutics Inc., which is focused on neurodegeneration.
Denali closed its IPO on Dec. 12 with the sale of nearly 16m shares at $18 each for gross proceeds...
Welcome to Scrip
Create an account to read this article
Already a subscriber?